BRPI0614761A2 - proteìnas de fusão de albumina - Google Patents
proteìnas de fusão de albuminaInfo
- Publication number
- BRPI0614761A2 BRPI0614761A2 BRPI0614761-5A BRPI0614761A BRPI0614761A2 BR PI0614761 A2 BRPI0614761 A2 BR PI0614761A2 BR PI0614761 A BRPI0614761 A BR PI0614761A BR PI0614761 A2 BRPI0614761 A2 BR PI0614761A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- albumin fusion
- vectors
- albumin
- host cells
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 7
- 108010088751 Albumins Proteins 0.000 title abstract 7
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
PROTEìNAS DE PUSãO DE ALBUMINA. A presente invenção engloba proteínas de fusão de albumina. Moléculas de ácido nucléico que codificam as proteínas de fusão de albumina da invenção também são englobadas pela invenção, assim como os vetores contendo estes ácidos nucléicos, células hospedeiras transformadas com estes vetores de ácidos nucléicos e métodos de preparar proteínas de fusão de albumina da invenção e usar estes ácidos nucléicos, vetores e/ou células hospedeiras. Adicionalmente, a presente invenção engloba composições farmacêuticas compreendendo proteínas de fusão de albumina e métodos de tratar, prevenir ou aliviar doenças, desordens ou condições usando proteínas de fusão de albumina da invenção.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70752105P | 2005-08-12 | 2005-08-12 | |
US71238605P | 2005-08-31 | 2005-08-31 | |
US73272405P | 2005-11-03 | 2005-11-03 | |
US77691406P | 2006-02-28 | 2006-02-28 | |
US78136106P | 2006-03-13 | 2006-03-13 | |
US81018206P | 2006-06-02 | 2006-06-02 | |
US81368206P | 2006-06-15 | 2006-06-15 | |
PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0614761A2 true BRPI0614761A2 (pt) | 2009-05-19 |
Family
ID=37758042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614761-5A BRPI0614761A2 (pt) | 2005-08-12 | 2006-07-31 | proteìnas de fusão de albumina |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1924596A4 (pt) |
JP (1) | JP2009504157A (pt) |
KR (1) | KR20080071119A (pt) |
AU (1) | AU2006280312A1 (pt) |
BR (1) | BRPI0614761A2 (pt) |
CA (1) | CA2618476A1 (pt) |
EC (1) | ECSP088262A (pt) |
IL (1) | IL189246A0 (pt) |
MA (1) | MA29836B1 (pt) |
MX (1) | MX2008001865A (pt) |
NO (1) | NO20081233L (pt) |
TN (1) | TNSN08064A1 (pt) |
WO (1) | WO2007021494A2 (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
BRPI0716744A2 (pt) * | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | proteínas de fusão de albumina |
WO2008094538A2 (en) | 2007-01-30 | 2008-08-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
WO2009150284A2 (es) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Conjugados de apo-a para la administración de compuestos biológicamente activos |
SG172940A1 (en) | 2009-01-16 | 2011-08-29 | Teva Pharma | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
CN106977608A (zh) | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
KR101969526B1 (ko) * | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 악성 종양 전이 억제용 의약 |
CN110272484A (zh) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
UY34401A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
BR112014017165B1 (pt) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos |
CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
WO2013122617A1 (en) | 2012-02-15 | 2013-08-22 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
CN104736559B (zh) | 2012-03-16 | 2022-04-08 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
JP2015521589A (ja) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | プロコアグラント化合物 |
CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
EP4269431A1 (en) | 2012-07-11 | 2023-11-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
PL3889173T3 (pl) | 2013-02-15 | 2023-12-11 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
BR112016015512B1 (pt) | 2014-01-10 | 2023-12-19 | Bioverativ Therapeutics Inc | Proteína quimérica, composição farmacêutica e seus usos |
EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
JP6625627B2 (ja) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | アデノシンデアミナーゼ−2(ada2)、その変異体の組成物およびそれを使用する方法 |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
CN108472337B (zh) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | 因子ix融合蛋白以及其制备和使用方法 |
EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
JP7005019B2 (ja) | 2015-10-02 | 2022-02-04 | シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド | 組織修復のための二重特異性治療用タンパク質 |
CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
SG10201913278PA (en) | 2016-02-01 | 2020-02-27 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Fc受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
KR20190091292A (ko) | 2016-12-02 | 2019-08-05 | 바이오버라티브 테라퓨틱스 인크. | 응고 인자에 대한 면역 내성 유도 방법 |
BR112019011115A2 (pt) | 2016-12-02 | 2019-10-01 | Bioverativ Therapeutics Inc | métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos |
US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3576762A1 (en) | 2017-01-31 | 2019-12-11 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
MA50141A (fr) * | 2017-04-20 | 2020-07-29 | Novo Nordisk As | Procédés de purification de protéines de fusion d'albumine |
EP3665289A1 (en) | 2017-08-09 | 2020-06-17 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
MX2020008152A (es) | 2018-02-01 | 2020-11-24 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor viii. |
CA3108799A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
AU2019393880A1 (en) | 2018-12-06 | 2021-07-15 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor IX |
EP4038182A1 (en) | 2019-09-30 | 2022-08-10 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
WO2022030580A1 (ja) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途 |
WO2024080306A1 (ja) * | 2022-10-11 | 2024-04-18 | Jcrファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2545090T3 (es) * | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
AU2005211725B2 (en) * | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en active Application Filing
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1924596A4 (en) | 2009-07-29 |
JP2009504157A (ja) | 2009-02-05 |
NO20081233L (no) | 2008-05-09 |
IL189246A0 (en) | 2008-08-07 |
AU2006280312A1 (en) | 2007-02-22 |
CA2618476A1 (en) | 2007-02-22 |
ECSP088262A (es) | 2008-05-30 |
WO2007021494A3 (en) | 2007-07-26 |
WO2007021494A2 (en) | 2007-02-22 |
TNSN08064A1 (en) | 2009-07-14 |
KR20080071119A (ko) | 2008-08-01 |
EP1924596A2 (en) | 2008-05-28 |
MA29836B1 (fr) | 2008-10-03 |
MX2008001865A (es) | 2008-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0614761A2 (pt) | proteìnas de fusão de albumina | |
BRPI0507026A (pt) | proteìnas de fusão de albumina | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
WO2007146038A3 (en) | Albumin fusion proteins | |
WO2003059934A3 (en) | Albumin fusion proteins | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
MX2019007753A (es) | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida. | |
BR112015005674A2 (pt) | variantes e métodos de uso de hppd | |
BR112014007469A2 (pt) | arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas | |
BR112015012152A2 (pt) | Proteína de fusão terapêutica direcionada que compreende uma enzima lisossomal, ácido nucleico, composição farmacêutica, método para produzir a dita proteína e usos da proteína para tratar uma doença de armazenamento lisossomal e mucopolissacaridose tipo iiib | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
WO2001079443A3 (en) | Albumin fusion proteins | |
WO2008142164A3 (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders | |
BRPI0911385A2 (pt) | mutantes fgf21 e seus usos | |
ATE548381T1 (de) | Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus | |
BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
BRPI1010880A2 (pt) | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. | |
MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
WO2008065372A3 (en) | Modified erythropoietin polypeptides and uses thereof for treatment | |
EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
BR112014026531A2 (pt) | proteínas de ligação de antígeno ligando cd30 humano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE. |